Clinical management of myelodysplastic syndromes: Update of SIE, SIES, GITMO practice guidelines

Leukemia Research

Volumn 34, Issue 12, 2010, Pages 1576-1588

  Santini, V ^a   Alessandrino, P E ^b   Angelucci, E ^c   Barosi, G ^b   Billio, A ^d   Di Maio, M ^e   Finelli, C ^f   Locatelli, F ^g   Marchetti, M ^h   Morra, E ⁱ   Musto, P ^j   Visani, G ^k   Tura, S ^f  

^a UNIVERSITY OF FLORENCE   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c Ospedale Oncologico A Businco   (Italy)

^d Ospedale Centrale   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

^h Unit of Haematology   (Italy)

ⁱ OSPEDALE NIGUARDA CA GRANDA   (Italy)

^j REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^k SAN SALVATORE HOSPITAL   (Italy)

more..

Author keywords

Clinical practice guidelines; Del5q; Hematopoietic growth factors; HSCT; Hypomethylating therapy; Immunomodulating agents; Immunosuppressive therapy; Iron chelation; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIANEMIC AGENT; AZACITIDINE; CYCLOSPORIN A; CYTARABINE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ELTROMBOPAG; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IDARUBICIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ROMIPLOSTIM; THALIDOMIDE; THYMOCYTE ANTIBODY; TOPOTECAN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHELATION THERAPY; CHROMOSOME 5Q; CHROMOSOME DELETION; CLINICAL TRIAL; COMORBIDITY; CONTINUOUS INFUSION; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE MYELOMONOCYTIC LEUKEMIA; KIDNEY DISEASE; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; SURVIVAL; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 77954072094     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.01.018     Document Type: Article

References (167)

1. Oliva E.N., Clissa C., Santini V., et al. Quality of life assessment in patients affected by myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):2363.
2. Greenberg P.L., Cosler L.E., Ferro S.A., et al. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw 2008, 6(9):942-953.
3. Alessandrino E.P., Amadori S., Barosi G., et al. Evidence- and consensus-based guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Haematology. Haematologica 2002, 87:1286-1306.
4. Barosi G., Carella A., Lazzarino M., et al. Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Haematology, the Italian Society of Experimental Haematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2005, 90:1236-1257.
5. Harbour R., Miller J. A new system for grading recommendations in evidence based guide-lines. BMJ 2001, 323:334-336.
6. Swerdlow S.H., Campo E., Harris N.L., et al. World Health Organization classification of tumours of the hematopoietic and lymphoid tissues 2008, WHO Press.
7. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
8. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25(23):3503-3510.
9. Park M.J., Kim H.J., Kim S.H., et al. Is international prognostic scoring system (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO classification-based prognostic scoring system (WPSS) and comparison with IPSS. Eur J Haematol 2008, 81:364-373.
10. Sanz G., Nomdedeu B., Such E., et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):640.
11. Kantarjian H., O'Brien S., Ravandi F., et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008, 113(6):1351-1361.
12. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
13. Della Porta M.G., Malcovati L., Boveri E., et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009, 27(5):754-762.
14. Hellström-Lindberg E., Gulbrandsen N., Lindberg G., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003, 120(6):1037-1046.
15. Wang S.A., Pozdnyakova O., Jorgensen J.L., et al. Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica 2009, 94:29-37.
16. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia group B. J Clin Oncol 2002, 20:2429-2440.
17. Silverman L.R., McKenzie B.R., Peterson B.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-3903.
18. Kantarjian H., Issa J.P., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
19. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. International Vidaza high-risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10(3):223-232.
20. Wijermans P., Suciu S., Baila L., et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final result of the randomized phase III study (06011) of EORTC Leukemia and German MDS Study Groups. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):226.
21. Kornblith A.B., Herndon J.E., Silverman L.R., et al. Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002, 20(10):2441-2452.
22. Seymour J.F., Fenaux P., Silverman L.B., et al. Effects of azacitidine (AZA) vs conventional care regimens (CCR) in elderly (75 years) patients (Pts) with myelodysplastic syndromes (MDS) from the AZA-001 survival trial. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):3629.
23. Mufti G.J., Garcia-Manero G., Horvath N., et al. Prolonged survival in higher-risk myelodysplastic syndrome (MDS) patients (PTS) with -7/del(7Q) treated with azacitidine (AZA). Haematologica (EHA Annual Meeting Abstracts) 2008, 93(s1):369-370.
24. Lim Z.Y., Ho A.Y.L., Samuel J., et al. Outcomes of MDS patients with chromosome 7 abnormalities treated with 5-azacytidine. Blood (ASH Annual Meeting Abstracts) 2007, 110:1449.
25. List AF, Fenaux P, Mufti GJ, et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. 2008 ASCO Annual Meeting Abs 7006.
26. Lyons R.M., Cosgriff T.M., Modi S.S., et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009, 27(11):1850-1856.
27. Silverman L.R., Fenaux P., Mufti G.J., et al. The effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients (Pts) with myelodysplastic syndromes (MDS). Blood (ASH Annual Meeting Abstracts) 2008, 112(November):227.
28. Wijermans P.W., Lübbert M., Verhoef G., et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005, 84(Suppl. 1):9-17.
29. Kantarjian H.M., O'Brien S., Shan J., et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007, 109:265-273.
30. Kantarjian H., Oki Y., Garcia-Manero G., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukaemia. Blood 2007, 109:52-57.
31. Steensma DP, Baer MR, Slack JL, et al. A multicenter phase II trial of the decitabine alternative 5-day dosing regimen: analysis of efficacy in various subgroups of patients with myelodysplastic syndromes (MDS). 2008 ASCO Annual Meeting Abs 7032.
32. Bang S.M., Kim I.H., Park S., et al. Korean AML/MDS Working Party. The equal activity of azacitidine in 4 risk groups of IPSS in MDS. Blood (ASH Annual Meeting Abstracts) 2007, 110(November):4615.
33. Grinblatt D., Nearing M., Malone J., et al. AVIDA treatment of patients with low-risk myelodysplastic syndromes receiving azacitidine who are enrolled in AVIDA, a longitudinal patient registry. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):1646.
34. Musto P, Maurillo L, Spagnoli A, et al. 5-Azacytidine for the treatment of low/intermediate-1 IPSS risk myelodysplastic syndromes: results in 63 patients from the Italian patient named program. Cancer, 2010, in press.
35. Stadler M., Germing U., Kliche K.O., et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004, 18:460-465.
36. Passweg J.R., Giagounidis A., Simcock M., et al. Immunosuppression for patients with low and intermediate risk myelodysplastic syndrome: a prospective randomized multicenter trial comparing antithymocyte globulin+cyclosporine with best supportive care: SAKK 33/99. Blood (ASH Annual Meeting Abstracts) 2007, 110(November):1461.
37. Broliden P.A., Dahl I.M., Hast R., et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 2006, 91:667-670.
38. Sloand E.M., Wu C.O., Greenberg P., et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008, 26(15):2505-2511. [Epub 2008 Apr 14].
39. Chen S., Jiang B., Da W., et al. Treatment of myelodysplastic syndrome with cyclosporin A. Int J Hematol 2007, 85(January (1)):11-17.
40. Molldrem J.J., Leifer E., Bahceci E., et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002, 137:156-163.
41. Saunthararajah Y., Nakamura R., Nam J.M., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002, 100:1570-1574.
42. Saunthararajah Y., Nakamura R., Wesley R., et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003, 102:3025-3027.
43. Lim Z.Y., Killick S., Germing U., et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007, 21:1436-1441.
44. Strupp C., Germing U., Aivado M., et al. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002, 16:1-6.
45. Candoni A., Raza A., Silvestri F., et al. Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. Ann Hematol 2005, 84(7):479-481.
46. Musto P. Thalidomide therapy in adult patients with myelodysplastic syndrome: a north central cancer treatment group phase II trial. Cancer 2007, 109:1211-1212.
47. Moreno-Aspitia A., Colon-Otero G., Hoering A., et al. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer 2006, 107(4):767-772.
48. Bouscary D., Legros L., Tulliez M., et al. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies. Br J Haematol 2005, 131(5):609-618.
49. Tamburini J., Elie C., Park S., et al. Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leuk Res 2009, 33(4):547-550.
50. Nachtkamp K., Kündgen A., Strupp C., et al. Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 2009, 33(August (8)):1024-1028.
51. Kelaidi C., Park S., Brechignac S., et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res 2008, 32(7):1049-1053.
52. Musto P., Falcone A., Sanpaolo G., et al. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes. Leuk Res 2006, 30(4):385-388.
53. Steurer M., Sudmeier I., Stauder R., et al. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 2003, 121:101-103.
54. List A.F., Kurtin S., Roe D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549-557.
55. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
56. Raza A., Reeves J.A., Feldman E.J., et al. Phase II study of lenalidomide in transfusion-dependent, low- and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008, 11:86-93.
57. Giagounidis A., Fenaux P., Mufti G.J., et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 2008, 87(5):345-352.
58. Sekeres M.A., Maciejewski J.P., Giagounidis A.A., et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008, 26:5943-5949.
59. Göhring G, Giagounidis A, Büsche G et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol 2009;October 24. [Epub ahead of print].
60. List A.F., Giagounidis A., Brandenburg N., et al. Risk factors for AML transformation and mortality in transfusion-dependent deletion 5q mds. Haematologica (EHA Annual Meeting Abstracts) 2008, 93(June (s1)):287.
61. Ades L., Boehrer S., Prebet T., et al. Efficacy and safety of lenalidomide in intermediate-2-or high risk myelodysplastic syndromes (MDS) with 5q deletion: results of a phase II study. Blood 2009, 113(17):3947-3952.
62. Oosterveld M., Muus P., Suciu S., et al. EORTC, EBMT, SAKK, GIMEMA Leukemia Groups and the MD Anderson Cancer Center. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukaemia; two parallel studies adjusted for various prognostic factors. Leukemia 2002, 16:1615-1621.
63. Kantarjian H.M., O'Brien S., Huang X., et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007, 109:1133-1137.
64. Beran M., Shen Y., Kantarjian H., et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 2001, 92:1999-2015.
65. Kantarjian H., Beran M., Cortes J., et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006, 106:1099-1109.
66. Estey E.H., Thall P.F., Cortes J.E., et al. Comparison of idarubicin+ara-C-, fludarabine+ara-C, and topotecan+ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001, 98:3575-3583.
67. Hast R., Hellström-Lindberg E., Ohm L., et al. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia 2003, 17:1827-1833.
68. Ossenkoppele G.J., Graveland W.J., Sonneveld P., et al. Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 2004, 103:2908-2913.
69. Hofmann W.K., Heil G., Zander C., et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol 2004, 83:498-503.
70. Giles F.J., Kantarjian H.M., Cortes J.E., et al. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res 2005, 29:649-652.
71. Greenberg P.L., Lee S.J., Advani R., et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004, 22:1078-1086.
72. Tsimberidou A., Estey E., Cortes J., et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003, 97:1481-1487.
73. Virchis A., Koh M., Rankin P., et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol 2004, 124:26-32.
74. Vaena D.A., Walker P., Pennington K., et al. Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study. Leuk Res 2004, 28:49-52.
75. Zwierzina H., Suciu S., Loeffler-Ragg J., et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 2005, 19:1929-1933.
76. Denzlinger C., Bowen D., Benz D., et al. Low dose melphalan induces favourable response in elderly patients with high risk MDS or secondary acute AML. Br J Haematol 2000, 108:93-95.
77. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007, 25:4246-4254.
78. Sierra J., Pérez W.S., Rozman C., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002, 100:1997-2004.
79. de Witte T., Hermans J., Vossen J., et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000, 110:620-630.
80. Popat U., de Lima M.J., Ativitavas T., et al. Allogeneic transplantation (HCT) for myelodysplastic syndrome: recent MDACC experience. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):1131.
81. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002, 100:1201-1207.
82. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006, 20:128-135.
83. Alessandrino E.P., Della Porta M.G., Bacigalupo A., et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008, 112(3):895-902.
84. Cutler C.S., Lee S.J., Grenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579-585.
85. Castro-Malaspina H., Jabubowski A.A., Papadopoulos E.B., et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant 2008, 14:458-468.
86. Guardiola P., Runde V., Bacigalupo A., et al. Subcommittee for MDS of the CML Working Group of the EBMT Group. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002, 99:4370-4378.
87. del Cañizo M.C., Martínez C., Conde E., et al. Grupo Español de Trasplante Hematopoyético. Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry. Bone Marrow Transplant 2003, 32:987-992.
88. Kröger N. Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS. Hematology 2008, 60-67.
89. Al-Ali H.K., Brand R., van Biezen A., et al. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the CL Working Party of the EBMT. Leukemia 2007, 21:1945-1951.
90. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor recipient HLA-matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
91. Majhail N.S., Brunstein C.G., Tomblyn M., et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant 2008, 14:82-91.
92. Martino R., Iacobelli S., Brand R., et al. Myelodysplastic syndrome subcommittee of the Chronic Leukemia Working Party of the EBMT Group. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006, 108:836-846.
93. Baronciani D., Rambaldi A., Iori A.P., et al. Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. Am J Hematol 2008, 83(9):717-720.
94. Kroger N., Shimoni A., Zabelina T., et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 2006, 37:339-344.
95. Parker J.E., Shafi T., Pagliuca A., et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 2002, 119:144-154.
96. Alessandrino E.P., Malcovati L., La Nasa G., et al. Reduced intensity conditioning with thiotepa and fludarabine for allogeneic transplantation: evidence for low toxicity and long-lasting disease control in MDS with low/intermediate-1 IPSS score and in AML from MDS in complete remission. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):3285.
97. Stewart B., Verdugo M., Guthrie K.A., et al. Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes. Br J Haematol 2003, 123:879-885.
98. Yakoub-Agha I., de la Salmonière P., Ribaud P., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of Bone Marrow Transplantation. J Clin Oncol 2000, 18:963-971.
99. Laport G.G., Sandmaier B.M., Storer B.E., et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008, 14:246-255.
100. Czibere A., Graef T., Lind J., et al. 5-Azacitidine in combination with donor lymphocyte infusion for treatment of patients with MDS or AML relapsing after allogeneic stem cell transplantation. Blood 2006, 108. [Abs 5341].
101. de Lima M., Padua L., Giralt S., et al. A dose and schedule finding study of maintenance therapy with low dose 5-azacitidine after allogeneic stem cell transplantation for high-risk AML and MDS. Blood 2007, 110. [Abs 3012].
102. Lübbert M., Bertz H., Rüter B.H., et al. Non-intensive AML/MDS treatment with low-dose decitabine prior to reduced-intensity conditioning and allogeneic blood stem cell transplantation of older patients. Blood 2006, 108. [Abs 5257].
103. McCarty, Shickle L., Roberts C.H., et al. 5-Azacitidine prior to allogeneic transplantation effectively reduces relapse, TRM and overall mortality in high risk myelodysplasia and secondary AML [abstract]. Bone Marrow Transplant 2008, 41(Suppl. 1). [Abs 746].
104. de Padua Silva L., de Lima M., Kantarjian H., et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009, 43(June (11)):839-843.
105. Ross S.D., Allen E., Probst C.A., et al. A systematic review and meta-analysis efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndromes. Oncologist 2007, 12:1264-1273.
106. Moyo V., Lefebvre P., Duh M.S., et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008, 87(July (7)):527-536.
107. Mundle S., Lefebvre P., Vekeman F., et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 2009, 115(4):706-715.
108. Park S., Grabar S., Kelaidi C., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008, 111(January (2)):574-582.
109. Latagliata R., Oliva E.N., Volpicelli P., et al. Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes. Acta Haematol 2008, 120(2):104-107.
110. Villegas A., Arrizabalaga B., Fernández-lago C., et al. Treatment of anemia with darbepoetin alfa in patients with low and intermediate-1 risk myelodysplastic syndromes. Results from the ARAMYS study. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):3451.
111. Gabrilove J., Paquette R., Lyons R.M., et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008, 142(3):379-393.
112. Hellström-Lindberg E., Gulbrandsen N., Lindberg G., et al. Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003, 120(March):1037-1046.
113. Gotlib J., Lavori P., Quesada S., et al. A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol 2009, 84:15-20.
114. Casadevall N., Durieux P., Dubois S., et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004, 104:321-327.
115. Balleari E., Rossi E., Clavio M., et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol 2006, 85:174-180.
116. Jädersten M., Malcovati L., Dybedal I., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008, 26(July (21)):3607-3613.
117. Kantarjian H., Fenaux P., Sekeres M.A., et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010, 28(January (3)):437-444. Epub 2009 Dec 14.
118. Dreyfus F. The deleterious effects of iron overload in patients with myelodysplastic syndromes. Blood Rev 2008, 22:S29-S34.
119. Della Porta M.G., Kuendgen A., Malcovati L., et al. Myelodysplastic syndrome (MDS)-Specific comorbidity index for predicting the impact of extra-hematological comorbidities on survival of patients with MDS. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):2677.
120. Di Tucci A.A., Matta G., Deplano S., et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008, 93:1385-1388.
121. Armand P., Kim H.T., Cutler C.S., et al. Prognostic impact of elevated pre-transplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007, 109:4586-4588.
122. Platzbecker U., Bornhäuser M., Germing U., et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 2008, 14(November (11)):1217-1225.
123. Angelucci E., Barosi G., Camaschella C., et al. Italian Society haematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008, 93:741-752.
124. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008, 88:24-29.
125. Bennett J.M. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008, 83(November (11)):858-861. MDS Foundation's Working Group on transfusional iron overload.
126. Rose C., Brechignac S., Vassilief D., et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood (ASH Annual Meeting Abstracts) 2007, 110(November):249.
127. Leitch H.A., Goodman T.A., Wong K.K., et al. Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy. Blood (ASH Annual Meeting Abstracts) 2006, 108(November):249.
128. ®) in patients with transfusion-dependent anemias: 1-year results from the large, prospective, multicenter EPIC study. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):3875.
129. Porter J., Galanello R., Saglio G., et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008, 80:168-176.
130. ®) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):633.
131. Miyazawa K., Ohyashiki K., Urabe A., et al. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan. Int J Hematol 2008, 88:73-81.
132. Metzgeroth G., Dinter D., Schultheis B., et al. Deferasirox in MDS patients with transfusion-caused iron overload-a phase-II study. Ann Hematol 2009, 88(April):301-310.
133. Min Yoo-Hong, Kim Hyeoung Joon, Lee Kyoo Hyung, et al. A multi-center, open label study evaluating the efficacy of iron chelation therapy with deferasirox in transfusional iron overload patients with myelodysplastic syndromes or aplastic anemia using quantitative R2 MRI. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):3649.
134. Messa E., Cilloni D., Messa F., et al. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008, 120:70-74.
135. Hasle H., Niemeyer C.M., Chessells J.M., et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003, 17:277-282.
136. Niemeyer C.M., Aricò M., Basso G., et al. Chronic myelomonocytic leukemia in childhood: a report of 110 cases. Blood 1997, 89:3534-3543.
137. Niemeyer C., Locatelli F. Chronic myeloproliferative disorders. Childhood leukemias, 2nd ed. 2006, 571-598. Cambridge University Press. C.H. Pui (Ed.).
138. Kardos G., Baumann I., Passmore S.J., et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003, 102:1997-2003.
139. Hasle H., Baumann I., Bergstrasser E., et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004, 18:2008-2014.
140. Sasaki H., Manabe A., Kojima S., et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia 2001, 15:1713-1720.
141. Passmore S.J., Chessells J.M., Kempski H., et al. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 2003, 121:758-767.
142. Woods W.G., Barnard D.R., Alonzo T.A., et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol 2002, 20:434-440.
143. Locatelli F., Niemeyer C., Angelucci E., et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 1997, 15:566-573.
144. Smith F.O., King R., Nelson G., et al. National Marrow Donor Program. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol 2002, 116:716-724.
145. Locatelli F., Nollke P., Zecca M., et al. European Working Group on Childhood MDS; European Blood and Marrow Transplantation Group. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 2005, 105:410-419.
146. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 2002, 16:645-649. On behalf of the MDS Committee of the Japanese Society of Pediatric Hematology.
147. Archambeault S., Flores N.J., Yoshimi A., et al. Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood 2008, 111:1124-1127.
148. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005, 19:971-977. On behalf of European Working Group of MDS in Childhood (EWOG-MDS).
149. Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia 2007, 21:556-560. On behalf of the European Working Group of MDS in Childhood (EWOG-MDS).
150. Niemeyer C., Kratze C. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol 2008, 140:610-624.
151. Locatelli F., Pession A., Bonetti F., et al. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. Leukemia 1994, 8:844-849.
152. Yusuf A., Frangoul H.A., Gooley T.A., et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 2004, 33:805-814.
153. Woodard P., Barfield R., Hale G., et al. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatr Blood Cancer 2006, 47:931-935.
154. Hasle H., Kerndrup G., Yssing M., et al. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia 1996, 10:1269-1273.
155. Niemeyer C., Duffner U., Bender-Gotze C., et al. AML-type intensive chemotherapy prior to stem cell transplantation (SCT) does not improve survival in children and adolescents with primary myelodysplastic syndromes (MDS). Blood 2000, 96(Suppl. 1):521a.
156. Strahm B., Locatelli F., Bader P., et al. on behalf of the EWOG-MDS Study Group Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant 2007, 40:329-333.
157. Yoshimi A., Baumann I., Führer M., et al. Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia. Haematologica 2007, 92:397-400.
158. http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf.
159. Voso M.T., Santini V., Finelli C., et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009, 15:5002-5007.
160. Kuendgen A., Strupp C., Hildebrandt B., et al. Results of a phase 2 trial with valproic acid alone or in combination with all-trans-retinoic acid (ATRA) in 29 patients with myelodysplastic syndromes. Blood (ASH Annual Meeting Abstracts) 2004, 104(November):1434.
161. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108(November (10)):3271-3279.
162. Gore S.D., Jiemjit A., Silverman L.B., et al. Combined methyltransferase/histone deacetylase inhibition with 5-azacitidine and MS-275 in patients with MDS, CMMoL and AML: clinical response, histone acetylation and DNA damage. Blood (ASH Annual Meeting Abstracts) 2006, 108(November):517.
163. Garcia-Manero G., Silverman L.B., Gojo I., et al. A randomized phase IIa study of vorinostat in patients with low or intermediate-1 risk myelodysplastic syndromes: preliminary results. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):5084.
164. Silverman L.R., Verma A., Odchimar-Reissig R., et al. A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (AZAC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a study of the New York Cancer Consortium. Blood (ASH Annual Meeting Abstracts) 2008, 112(November):3656.
165. Raza A., Mehdi M., Mumtaz M., et al. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 2008, 113(7):1596-1604.
166. Nand S., Godwin J., Smith S., et al. Azacitidine plus gemtuzumab ozogamicin (GO): a novel combination in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly. Blood (ASH Annual Meeting Abstracts) 2006, 108(November):1981.
167. ® (Azacitidine) in patients with advanced myelodysplastic syndromes (MDS). Blood (ASH Annual Meeting Abstracts) 2007, 110(November):1458.